Pancreatic Cancer News from Poster Sessions

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX). First Author: Julien Taieb, Sorbonne Paris Cite ́, Paris Descartes University, Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, Paris, France

J Clin Oncol 36, 2018 (suppl; abstr 4107)


Sequential treatment with Nab-paclitaxel plus Gemcitabine and Folfirinox in metastatic pancreatic adenocarcinoma: GABRINOX phase II results. First Author: Eric Assenat, Institut du Cancer de Montpellier (ICM), Univ Montpellier, Montpellier, France

J Clin Oncol 36, 2018 (suppl; abstr 4109)


Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer. First Author: Nathan Bahary, University of Pittsburgh Medical Center Cancer Center Pavilion, Pittsburgh, PA

J Clin Oncol 36, 2018 (suppl; abstr 4115)